Home › Research › Biomarkers
T1R2/T1R3 Identified as the Aβ Receptor: A New Mechanism Linking Aβ42/40 Ratio to Neuronal Hyperexcitability in Alzheimer’s Disease
Saito ML, Saito MR.. bioRxiv, 2026-10-01
Topic: Disease mechanisms in lab and animal studies
Plain-language summary
Early neuronal hyperexcitability is a hallmark of Alzheimer’s disease (AD) and correlates with cognitive decline. A key diagnostic indicator is the reduction in soluble Aβ42/40 ratio - from ∼10% in cognitively normal individuals to ∼5% in AD - which reliably predicts progression to dementia. Although widely used as a biomarker, whether this ratio plays an active signaling role has remained unclear. Building on our prior finding that T1R3 is required for Aβ25–35–mediated enhancement of voltage-gated sodium current (INa), we now show that the AD-associated 5% Aβ42/40 ratio functions as an active ligand that increases INa, whereas the physiological ∼10% ratio is inert. This effect requires T1R2 and T1R3, but not T1R1, identifying T1R2/T1R3 as the receptor responsible for Aβ ratio sensing. Human cell lines expressing Nav1.1, Nav1.5, or Nav1.6, as well as differentiated SH-SY5Y cells, all respond selectively to the active ratio. Rodent NG108-15 cells are natively insensitive, but expression of human T1R3 confers responsiveness, indicating a human-specific detection mechanism. These findings identify T1R2/T1R3 as the receptor that detects the Aβ42/40 ratio, link early Aβ changes to hyperexcitability, and point to a therapeutic target for restoring early neuronal function. The human-specific nature of this pathway motivates development of humanized T1R2/T1R3 knock-in mice for in vivo validation. Significance Statement In Alzheimer’s disease progression, neuronal hyperexcitability is one of the underlying causes, yet its molecular mechanism remains unknown. Here we report that the pathological Aβ42/40 ratio, a cerebrospinal fluid biomarker of Alzheimer’s disease, enhances voltage-gated sodium current, the major driving force of action potential generation. We identify the receptor responsible for this effect as an extra-oral sweet taste receptor, T1R2/T1R3. This mechanism is human-specific because rodent cells are insensitive to the pathological Aβ42/40 ratio, providing a molecular clue to why rodent models fail to recapitulate early Alzheimer’s disease. These findings identify T1R2/T1R3 as a molecular entry point at which the earliest biochemical change in AD is converted into neuronal dysfunction, making it a valid target for therapeutic intervention.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Saito, M. L., & Saito, M. R. (2026). T1R2/T1R3 Identified as the Aβ Receptor: A New Mechanism Linking Aβ42/40 Ratio to Neuronal Hyperexcitability in Alzheimer’s Disease. bioRxiv. https://doi.org/10.64898/2026.09.25.754367
Vancouver
Saito ML, Saito MR. T1R2/T1R3 Identified as the Aβ Receptor: A New Mechanism Linking Aβ42/40 Ratio to Neuronal Hyperexcitability in Alzheimer’s Disease. bioRxiv. 2026. doi:10.64898/2026.09.25.754367.
BibTeX
@article{saito2026-92b1327f,
author = {Saito, M. L. and Saito, M. R.},
title = {{T1R2/T1R3 Identified as the Aβ Receptor: A New Mechanism Linking Aβ42/40 Ratio to Neuronal Hyperexcitability in Alzheimer’s Disease}},
journal = {bioRxiv},
year = {2026},
doi = {10.64898/2026.09.25.754367},
url = {https://doi.org/10.64898/2026.09.25.754367}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- These findings identify T1R2/T1R3 as the receptor that detects the Aβ42/40 ratio, link early Aβ changes to hyperexcitability, and point to a therapeutic target for restoring early neuronal function.
- These findings identify T1R2/T1R3 as a molecular entry point at which the earliest biochemical change in AD is converted into neuronal dysfunction, making it a valid target for therapeutic intervention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 21 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 13 of the 62 points we could judge it on, which is 21 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (bioRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 13 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 13 of the 62 points we could judge it on is 21 out of 100. |
| Total | 21 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “dendritic”
287 studies in the library carry the topic tag “dendritic”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 287 tagged studies.